OverviewSuggest Edit

Emmaus Life Sciences is a biopharmaceutical company that provides treatments and therapies for rare and orphan diseases. It focuses on such genetic disorders as sickle cell disease. The company develops an oral pharmaceutical grade L-glutamine treatment for sickle cell anemia and sickle ß0-thalassemia.
TypePublic
Founded2000
HQTorrance, US
Websiteemmausmedical.com

Latest Updates

Employees (est.) (Feb 2020)21
Revenue (FY, 2018)$1.3 M(+924%)
Share Price (Sept 2020)$1.2
Cybersecurity ratingBMore

Key People/Management at Emmaus Life Sciences

Yutaka Niihara

Yutaka Niihara

Chief Executive Officer, Chairman of the Board
Yasushi Nagasaki

Yasushi Nagasaki

Senior Vice President of Finance
Willis C. Lee

Willis C. Lee

Chief Operating Officer, Vice-Chairman of the Board
George Sekulich

George Sekulich

Senior Vice President of Global Commercialization and Chief Information Officer
Dale E. Short

Dale E. Short

General Counsel
Masaharu Osato

Masaharu Osato

Director
Show more

Emmaus Life Sciences Office Locations

Emmaus Life Sciences has an office in Torrance
Torrance, US (HQ)
21250 Hawthorne Blvd #800
Show all (1)

Emmaus Life Sciences Financials and Metrics

Emmaus Life Sciences Revenue

Emmaus Life Sciences's revenue was reported to be $1.32 m in FY, 2018
USD

Revenue (Q3, 2019)

6.1m

Gross profit (Q3, 2019)

5.9m

Gross profit margin (Q3, 2019), %

97.1%

Net income (Q3, 2019)

(26.1m)

EBIT (Q3, 2019)

(3.6m)

Market capitalization (15-Sept-2020)

56.8m

Closing stock price (15-Sept-2020)

1.2

Cash (30-Sept-2019)

13.5m

EV

43.9m
Emmaus Life Sciences's current market capitalization is $56.8 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

745.9k135.1k100.1k85.1k128.5k1.3m

Cost of goods sold

147.1k132.0k142.6k73.0k4.9k5.5k53.5k827.4k

Gross profit

598.8k62.1k95.2k79.6k75.0k488.1k

Gross profit Margin, %

80%46%95%94%58%37%
Quarterly
USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

197.8k184.3k214.1k190.8k22.7k20.9k31.0k24.7k20.7k21.1k22.2k31.9k40.4k122.0k459.9k391.7k387.1k460.1k6.1m

Cost of goods sold

37.8k39.2k35.9k35.5k31.4k35.6k38.8k37.6k29.4k5.2k1.1k1.8k1.2k1.2k1.4k1.5k3.7k3.8k16.2k84.9k298.3k244.2k225.1k296.3k178.0k

Gross profit

160.0k145.1k178.2k155.3k21.6k19.1k29.8k23.5k19.3k19.6k18.5k28.1k24.2k37.1k161.6k147.5k162.0k163.8k5.9m

Gross profit Margin, %

81%79%83%81%95%91%96%95%93%93%83%88%60%30%35%38%42%36%97%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

93.4k7.7k1.3m1.2m432.1k318.2k5.4m3.3m

Accounts Receivable

54.4k12.4k26.6k9.3k11.8k5.1k6.5k63.3k

Prepaid Expenses

72.1k43.7k63.7k58.2k46.9k18.8k22.0k134.7k

Current Assets

322.9k81.7k1.4m1.3m548.2k1.2m5.7m3.5m
Quarterly
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(8.9m)(3.4m)(10.9m)(2.7m)(3.4m)(5.9m)(7.1m)(10.3m)

Depreciation and Amortization

11.9k18.8k13.0k10.3k7.6k7.2k48.7k117.9k

Accounts Payable

615.3k1.4m(63.4k)(153.9k)(15.8k)(182.9k)301.5k(432.7k)

Cash From Operating Activities

(4.2m)(2.3m)(3.0m)(3.3m)(2.1m)(3.0m)(4.8m)(9.0m)
USDQ3, 2011

Financial Leverage

-0.1 x
Show all financial metrics

Emmaus Life Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Emmaus Life Sciences Online and Social Media Presence

Embed Graph

Emmaus Life Sciences News and Updates

Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial

--Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue-- TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today preliminary top-line data for two patients who most recently co…

Emmaus Life Sciences Provides Update in Response to the Coronavirus (COVID-19) Pandemic

Within the overall SCD community, Emmaus is working in coordination with the Sickle Cell Disease Association of America and other organizations to educate and communicate with the SCD community during this challenging time. For more information, please visit:read more

Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum March 26th

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive present…

Emmaus Life Sciences Frequently Asked Questions

  • When was Emmaus Life Sciences founded?

    Emmaus Life Sciences was founded in 2000.

  • Who are Emmaus Life Sciences key executives?

    Emmaus Life Sciences's key executives are Yutaka Niihara, Yasushi Nagasaki and Willis C. Lee.

  • How many employees does Emmaus Life Sciences have?

    Emmaus Life Sciences has 21 employees.

  • What is Emmaus Life Sciences revenue?

    Latest Emmaus Life Sciences annual revenue is $1.3 m.

  • What is Emmaus Life Sciences revenue per employee?

    Latest Emmaus Life Sciences revenue per employee is $62.6 k.

  • Who are Emmaus Life Sciences competitors?

    Competitors of Emmaus Life Sciences include LogicBio Therapeutics, Rocket Pharmaceuticals and Benitec Biopharma.

  • Where is Emmaus Life Sciences headquarters?

    Emmaus Life Sciences headquarters is located at 21250 Hawthorne Blvd #800, Torrance.

  • Where are Emmaus Life Sciences offices?

    Emmaus Life Sciences has an office in Torrance.

  • How many offices does Emmaus Life Sciences have?

    Emmaus Life Sciences has 1 office.